DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) Drug Patent Profile
✉ Email this page to a colleague
When do Doxorubicin Hydrochloride (liposomal) patents expire, and what generic alternatives are available?
Doxorubicin Hydrochloride (liposomal) is a drug marketed by Ayana Pharma Ltd, Baxter Hlthcare Corp, Dr Reddys, Fordoz, Sun Pharm, and Zydus Lifesciences. and is included in six NDAs.
The generic ingredient in DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Doxorubicin Hydrochloride (liposomal)
A generic version of DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) was approved as doxorubicin hydrochloride by PFIZER on December 23rd, 1987.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)?
- What are the global sales for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)?
- What is Average Wholesale Price for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)?
Summary for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 102 |
| Clinical Trials: | 384 |
| Patent Applications: | 4,394 |
| DailyMed Link: | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) at DailyMed |
-patent-expirations.png "DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) drug patent expirations")
Recent Clinical Trials for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| CarThera | Phase 2 |
| Agenus Inc. | Phase 2 |
| Yonsei University | Phase 2 |
See all DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) clinical trials
Pharmacology for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
| Drug Class | Anthracycline Topoisomerase Inhibitor |
| Mechanism of Action | Topoisomerase Inhibitors |
US Patents and Regulatory Information for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ayana Pharma Ltd | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 207228-001 | Oct 12, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Fordoz | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 215178-001 | Jul 16, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Baxter Hlthcare Corp | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 212219-002 | Oct 19, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| YES Pharmaceutical Development Services GmbH | Celdoxome pegylated liposomal | doxorubicin hydrochloride | EMEA/H/C/005330 Celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.for treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts (< 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.Celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline). |
Authorised | no | no | no | 2022-09-15 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
